We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

The AUDACITY Study (AllUrion Device in Adults With Clinical ObesITY) (AUDACITY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05368259
Recruitment Status : Recruiting
First Posted : May 10, 2022
Last Update Posted : February 6, 2023
Information provided by (Responsible Party):
Allurion Technologies

Brief Summary:
The objective for this clinical study is to provide FDA with clinical evidence regarding the effectiveness and safety of the AGBS + moderate intensity lifestyle modification therapy program, indwell time of the AGBS inside the stomach, and outcomes at 48 weeks.

Condition or disease Intervention/treatment Phase
Obesity Device: AGBS Not Applicable

Detailed Description:
Prospective, open-label, multi-center, randomized study comparing the AGBS + moderate intensity lifestyle modification therapy program vs. moderate intensity lifestyle modification therapy program for the treatment of adults with obesity.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1000 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Open-Label, Multi-Center, Randomized, Pivotal Safety and Efficacy Study of the Allurion Gastric Balloon System + Moderate Intensity Lifestyle Modification Therapy Program vs. Moderate Intensity Lifestyle Modification Therapy Program for the Treatment of Adults With Obesity
Actual Study Start Date : May 12, 2022
Estimated Primary Completion Date : June 1, 2024
Estimated Study Completion Date : August 1, 2024

Arm Intervention/treatment
Experimental: AGBS + Moderate Intensity Lifestyle Therapy Group
Patients randomized to treatment will receive the AGBS device
Device: AGBS
The AGBS is designed to promote weight loss in individuals with obesity. The AGBS includes the Allurion Balloon, which is a temporary gastric balloon that promotes weight loss in individuals with obesity. The AGBS consists of up to 2 balloons placed during a 1-year period.
Other Name: Allurion Gastric Balloon System (AGBS)

No Intervention: Moderate Intensity Lifestyle Therapy (CONTROL) Group
Patients randomized to the control arm will receive moderate-intensity lifestyle therapy.

Primary Outcome Measures :
  1. Responder Rate (RR) dichotomized at 5% TBWL at 48 week [ Time Frame: 48 weeks ]
    Responder Rate (RR) dichotomized at 5% TBWL at 48 weeks is significantly greater than 50%

  2. %TBWL is significantly greater than Control Group mean %TBWL at 48 weeks [ Time Frame: 48 weeks ]
    %TBWL is significantly greater than Control Group mean %TBWL at 48 weeks, with a super superiority margin of 3.0%

Secondary Outcome Measures :
  1. Responder Rate (RR) dichotomized at both 5% and 10% TBWL at both 16 and 24 weeks [ Time Frame: 48 weeks ]
    Responder Rate (RR) dichotomized at both 5% and 10% TBWL at both 16 and 24 weeks: RR per treatment will be assessed using an exact binomial test and compared between treatments using a two-sided Fisher Exact test; p-values will be descriptive statistics.

Other Outcome Measures:
  1. RR dichotomized at 10% TBWL at both 40 and 48 weeks [ Time Frame: 48 Weeks ]
    Among those receiving a second balloon, RR dichotomized at 10% TBWL at both 40 and 48 weeks: RR per treatment will be assessed using an exact binomial test and compared between treatments using a two-sided Fisher Exact test; p-values will be descriptive statistics.

  2. Change in body fatness as measured by Body Mass Index (BMI) at 24 and 48 weeks [ Time Frame: 48 Weeks ]
    Change in BMI (kg/m2) will be calculated as: BMI at follow-up - Baseline BMI Change in BMI will be assessed using a paired t-test within each treatment group and compared between treatments using a two-group unpaired t-test; p-values will be descriptive statistics.

  3. Change in metabolic parameters [ Time Frame: 48 Weeks ]
    Change from screening/baseline in metabolic parameters at 48 weeks. These include HbA1c, total cholesterol, HDL-C, LDL-C, Triglycerides and LFTs. Change in metabolic parameters will be assessed using a paired t-test within each treatment group and compared between treatments using a two-group unpaired t-test; p-values will be descriptive statistics.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   22 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Age ≥22 years and ≤ 65 years of age
  2. BMI ≥30 kg/m2 and ≤ 40 kg/m2
  3. Have signed study-specific Informed Consent Form
  4. Willing to comply with study requirements, including follow-up visits
  5. Documented negative pregnancy test in women of childbearing potential
  6. Women of childbearing potential not intending to become pregnant for the duration of study participation. (Note: Women of childbearing potential must not be nursing at the time of treatment).
  7. Fully ambulatory without any severe chronic orthopedic disease that requires reliance on crutches, walkers, or a wheelchair that could preclude exercise during the study
  8. At least one unsuccessful attempt at weight loss, such as self-administered, commercial, or medically supervised lifestyle therapy program attempted within the 24 months preceding enrollment

Exclusion Criteria:

  1. Unable to walk 400 meters (the length of one loop of a track and field race track) without the use of an assistance device (e.g. cane, crutches, walker, wheel chair)
  2. Symptomatic congestive heart failure, cardiac arrhythmia or unstable coronary artery disease
  3. Pre-existing significant respiratory disease such as chronic obstructive pulmonary disease (COPD), severe sleep apnea and pneumonia
  4. Previous bariatric surgery including adjustable gastric band and endoscopic sleeve gastroplasty, or likely to undergo bariatric surgery during the study period
  5. Previous use of an intragastric gastric balloon
  6. Current use of an intragastric device, PlenityTM and digital weight loss solutions (e.g. Noom or Calibrate)
  7. History of any cancer other than non-melanoma skin cancer or papillary thyroid cancer within the last 5 years
  8. Benign or malignant gastrointestinal tumors
  9. History of chronic pancreatitis or acute pancreatitis within 12 months of enrollment
  10. History of, or current, small bowel obstruction
  11. History of severe GI motility disorder, such as severe gastroparesis
  12. History of any esophageal, gastric, or small bowel surgery
  13. History of, or current inflammatory bowel disease
  14. Any history of intraperitoneal adhesions
  15. Any history of open abdominal or gynecological surgery and/or radiation therapy to the abdomen, with the exception of cesarean sections performed at least 12 months prior to study enrollment
  16. History of/or signs and symptoms of/or radiographic evidence of esophageal, gastric, or duodenal disease including, but not limited to hiatal hernia ≥5cm, inflammatory diseases, varices, severe gastroparesis, recent history of gastric or duodenal ulcers, stricture/stenosis, achalasia, severe GERD requiring maximal medical therapy, or LA Grade B, C, or D esophagitis
  17. Diagnosis of autoimmune connective tissue disorder (e.g. lupus, erythematous, scleroderma)
  18. Immunocompromised due to medications or medical disease or diagnosed with HIV
  19. History of genetic or endocrine causes of obesity not adequately controlled by medication, including hypothyroidism
  20. Type 1 diabetes or Type 2 diabetes with HgbA1c ≥ 7%, or treated with any anti-diabetic medications other than metformin
  21. Significant acute and/or chronic infections
  22. Severe coagulopathy defined as INR 1.5 or higher or platelet count <150, hepatic insufficiency, or cirrhosis
  23. Unable or unwilling to discontinue use of aspirin and/or nonsteroidal anti-inflammatory agents (NSAIDs) at least 7 days prior to Allurion Deployment and continuing for 7 days after the Allurion Balloon is excreted
  24. Currently taking the following medications (within 30 days prior to enrollment) and/or there is a need or anticipated need for these medications during the study: Excluded Medications Systemic corticosteroids Anticoagulant therapy (e.g., warfarin, dabigatran) or anti-platelet therapy Immunosuppressive therapy (e.g., azathioprine, cyclosporine) Narcotics, opiates, or benzodiazepines Insulin for treatment of diabetes Anti-seizure therapy (e.g., clonazepam, phenytoin) Anti-arrhythmics (e.g., amiodarone)
  25. Inability or unwillingness to take anti-emetics during the device residence
  26. Prescription or over-the- counter weight loss medication known to cause significant weight gain or weight loss within 90 days of study enrollment through study participation
  27. Uncontrolled or severe psychiatric disease other than mild depression with a patient health questionnaire score of 9 or below
  28. History of pulmonary embolism or deep venous thrombosis
  29. Has cardiac pacemaker or other electric implantable device
  30. Anemia defined as either:

    Hgb <11 g/dL for females, <12 g/dL for males

  31. Cessation of any nicotine product within 3 months of enrollment or plans to quit use during the study
  32. Documented total body weight loss of ≥ 5% anytime 6 months preceding enrollment
  33. Residing in a location without access to study site medical resources
  34. History of or currently active eating disorders including night eating syndrome (NES), bulimia, or binge eating disorder
  35. Unwilling to refrain from any reconstructive and/or cosmetic surgery that may affect body weight during the study such as mammoplasty and lipoplasty
  36. Current, or history of, illicit drug use (defined per state law) or excessive alcohol use
  37. Enrolled in another investigational study that has not completed the required primary endpoint follow-up period (Note: Subjects involved in a long-term surveillance phase of another study are eligible for enrollment in this study).
  38. Current Use (within the last month) of any smoked or non-smoked marijuana products that contain THC or unwilling to abstain from THC containing marijuana products during the trial.
  39. Any conditions that, in the opinion of each site investigator, may render the subject unable to complete the study with a likely final outcome, or lead to difficulties for subject compliance with study requirements, or could confound study data.
  40. Subject is not of sufficient medical health as determined by the Investigator to participate in the study.
  41. Employees/family members of Allurion Technologies or any of its affiliates or contractors
  42. Immediate employees/family members of the Investigator, sub- Investigators, or their medical office or practice, or surgical, bariatric or hospital organizations at which study procedures may be performed
  43. An immediate family member (by marriage or blood relationship) of another subject already enrolled in the study
  44. Positive breath or stool test for H. Pylori
  45. History of covid-19 with any residual symptoms
  46. Known or suspected allergies to polyurethane
  47. Uncontrolled high blood pressure defined as ≥160/100 mmHg with or without medications
  48. Uncontrolled high cholesterol or triglycerides defined as LDL ≥190 mg/dL or triglycerides ≥500 mg/dL
  49. Inability to swallow Allurion Practice Capsule

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05368259

Layout table for location contacts
Contact: Ken Malomo (508) 647-4000 kmalomo@allurion.com

Layout table for location information
United States, Arizona
HonorHealth Research Institute Recruiting
Scottsdale, Arizona, United States, 85258
Contact: Heather Braun         
Principal Investigator: James Swain, MD         
United States, California
Cedars-Sinai Recruiting
Los Angeles, California, United States, 90048
Contact: Joe Meza         
Principal Investigator: Rabindra Watson, MD         
United States, Colorado
University of Colorado, Anschutz Health and Wellness Center Recruiting
Aurora, Colorado, United States, 80045
Contact: Fernanda Pessorrusso         
Principal Investigator: Mihir Wagh, MD         
United States, Florida
University of Miami, Miller School of Medicine Recruiting
Doral, Florida, United States, 33166
Contact: Jennifer Hernandez         
Principal Investigator: Nestor De la Cruz-Munoz, MD         
United States, Indiana
Indiana University Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Suzette Schmidt         
Principal Investigator: Mark Gromski, MD         
United States, Massachusetts
Tufts Medical Center Recruiting
Boston, Massachusetts, United States, 02111
Contact: Stephanie Gomez         
Principal Investigator: Sajani Shah, MD         
United States, Missouri
Saint Luke's Hospital Kansas City Recruiting
Kansas City, Missouri, United States, 64111
Contact: Jaycie Halderman         
Principal Investigator: Sreenivasa Jonnalagada, MD         
Washington University Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Thomas Hollander         
Principal Investigator: Vladimir Kushnir, MD         
United States, North Carolina
Atrium Health Care Recruiting
Charlotte, North Carolina, United States, 28204
Contact: Erica White, MD       erica.white1@atriumhealth.org   
Principal Investigator: Keith Gersin         
United States, Tennessee
Vanderbilt Center for Surgical Weight Loss Recruiting
Nashville, Tennessee, United States, 37204
Contact: Kimberly Fields         
Principal Investigator: Wayne English, MD         
United States, Texas
UT Health Science Center at Houston Recruiting
Bellaire, Texas, United States, 77401
Contact: Angielyn Rivera         
Principal Investigator: Erik Wilson, MD         
BMI Texas Recruiting
San Antonio, Texas, United States, 78258
Contact: Crystal Valle         
Principal Investigator: Michael Seger, MD         
Sponsors and Collaborators
Allurion Technologies
Layout table for additonal information
Responsible Party: Allurion Technologies
ClinicalTrials.gov Identifier: NCT05368259    
Other Study ID Numbers: TRL-1000-0007
First Posted: May 10, 2022    Key Record Dates
Last Update Posted: February 6, 2023
Last Verified: February 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Nutrition Disorders
Body Weight